Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,777.70up ₹16.70 (0.95%)BSE ₹1,778.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,761.00.
30 Oct: open ₹1,769.00, high ₹1,855.00, low ₹1,766.20
52-week range of traded prices to 30 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,26,530 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.90
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 51,30,21833.2% delivered
Sun Pharmaceutical Industries share news and announcements
1,452 announcements, routine notices left out, newest first. Page 26 of 30.
Jul 2010
13 Jul · Board meeting
Interalia, to consider and take on record the un-audited quarterly financial results of the Company for the first quarter ended June 30, 2010.
Jun 2010
May 2010
24 May · Dividend
Board of Directors at its Meeting held on May 24, 2010 have recommended payment of dividend of Rs. 13.75 per equity share of Rs. 5/- each of the Company for the year ended March 31, 2010 subject to the approval of the members at the ensuing Annual General Meeting of the Company.24 May · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 410277 lacs for year ending on 31-MAR-2010 against Rs. 427230 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 135108 lacs for the year ending on 31-MAR-2010 against Rs. 181773 lacs for the year ending on 31-MAR-2009.24 May · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 184613 lacs for year ending on 31-MAR-2010 against Rs. 276975 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 89865 lacs for the year ending on 31-MAR-2010 against Rs. 126529 lacs for the year ending on 31-MAR-2009.7 May · Board meeting
Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2010. (2) To consider recommendation of payment of dividend on equity shares for the year ended March 31, 2010 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Apr 2010
26 Apr · Business
Press release dated April 24, 2010, titled " Sun Pharma : An update on generic Protonix(R) litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Apr · Business
Press release dated April 10, 2010, titled " Sun Pharma announces USFDA tentative approval for generic Namenda(R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Apr · Business
Press release dated April 08, 2010, titled " Sun Pharma announces USFDA approval for generic Wellbutrin SR(R) extended release tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Apr · Management
Board of directors of the Company has appointed Shri. Kal Sundaram, as an additional Director on the Board of Directors of the Company and as the Chief Executive Officer of the Company with effect from April 01, 2010.
Mar 2010
18 Mar · Business
Press release dated March 18, 2010, titled " Sun Pharma announces USFDA approval for generic Prometh Syrup ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
29 Jan · Business
Press release dated January 29, 2010, titled "Sun Pharma reports Q3 2009-10 financials; Q3: Net sales Rs.1021 crores, Net profit Rs.339 crores". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 48964 lacs for quarter ending on 31-DEC-2009 against Rs. 63106 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 31804 lacs for the quarter ending on 31-DEC-2009 against Rs. 25668 lacs for the quarter ending on 31-DEC-2008.29 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 102086 lacs for quarter ending on 31-DEC-2009 against Rs. 91827 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 33895 lacs for the quarter ending on 31-DEC-2009 against Rs. 40864 lacs for the quarter ending on 31-DEC-2008.12 Jan · Business
Press release dated January 12, 2010, titled "Sun Pharma to announce Q3 results on January 29, 2010". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Jan · Board meeting
Meeting on 29 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”11 Jan · Business
Press release dated January 11, 2010, titled "Sun Pharmaceutical Sends Letter to Directors of Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
31 Dec · Business
Press release dated December 31, 2009, titled "Taro Shareholders to Levitte and Directors: Quit the Board." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Dec · Business
Press release dated December 24, 2009, titled "RiskMetrics Recommends Taro Shareholders Vote Against Taro Board of Directors". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Dec · Business
Press release dated December 22, 2009, titled "Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for its Failures". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Dec · Business
Press release dated December 21, 2009, titled " PROXY Governance Recommends Against Taro's Board and Supports Sun". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Dec · Business
Press release dated December 17, 2009, titled " Sun Pharmaceutical Sends Letter to Taro Shareholders." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
26 Nov · Business
Press release dated November 26, 2009, titled "Sun Pharma announces USFDA tentative approval for generic Strattera Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Nov · Business
Press release dated November 18, 2009, titled "Sun Pharma announces USFDA approval for Nicardipine injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Nov · Business
Press release dated November 17, 2009, titled "Sun Pharma announces USFDA tentative approval for generic Gleevec (R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Nov · Business
Press release dated November 06, 2009, titled "Sun Pharma announces USFDA approval for generic Acular(R)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
28 Oct · Business
Press release dated October 28, 2009, titled "Sun Pharma reports Q2 2009-10 financials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 47439 lacs for quarter ending on 30-SEP-2009 against Rs. 69753 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 20306 lacs for the quarter ending on 30-SEP-2009 against Rs. 30314 lacs for the quarter ending on 30-SEP-2008.28 Oct · Results
Standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 88027 lacs for half year ending on 30-SEP-2009 against Rs. 136834 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 32457 lacs for the half year ending on 30-SEP-2009 against Rs. 58392 lacs for the half year ending on 30-SEP-2008.28 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 118517 lacs for quarter ending on 30-SEP-2009 against Rs. 117784 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 45381 lacs for the quarter ending on 30-SEP-2009 against Rs. 51277 lacs for the quarter ending on 30-SEP-2008.28 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 197276 lacs for half year ending on 30-SEP-2009 against Rs. 221961 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 61765 lacs for the half year ending on 30-SEP-2009 against Rs. 101421 lacs for the half year ending on 30-SEP-2008.23 Oct · Business
Press release relating to announcement of Earnings call for Q2 FY10 results. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Oct · Board meeting
Meeting on 28 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Sep 2009
16 Sep · Updates
Chairman's Speech delivered at the Annual General Meeting of the Company held on September 11, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Sep · Business
Press release dated September 14, 2009, titled "Sun Pharmaceutical Announces Expiration of HSR Act Waiting Period for Taro Tender Offer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Sep · Meeting
Proceedings of the Annual General Meeting of the Company held on September 11, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
31 Aug · Business
Press release dated August 28, 2009, titled "Sun Pharmaceutical Files HSR Application for Taro Tender Offer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Aug · Business
Press release dated August 13, 2009, titled "Sun Pharmaceutical to File HSR Application for Taro Tender Offer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Aug · Meeting
Notice of the Annual General Meeting of the members of the Company to be held on September 11, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Aug · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Business
Press release dated August 11, 2009, titled "Sun Pharma announces USFDA approval for generic Eloxatin and Imitrex ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Aug · Business
Press release dated August 03, 2009, titled "Sun Pharma signs agreement with MedImmune for generic Ethyol(R)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.